Zacks Research Has Optimistic Outlook of TEVA Q1 Earnings

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) - Stock analysts at Zacks Research upped their Q1 2026 earnings estimates for shares of Teva Pharmaceutical Industries in a research report issued to clients and investors on Wednesday, June 25th. Zacks Research analyst R. Department now anticipates that the company will earn $0.49 per share for the quarter, up from their previous estimate of $0.48. The consensus estimate for Teva Pharmaceutical Industries' current full-year earnings is $2.50 per share. Zacks Research also issued estimates for Teva Pharmaceutical Industries' FY2026 earnings at $2.61 EPS, Q1 2027 earnings at $0.65 EPS and FY2027 earnings at $2.81 EPS.

Other research analysts also recently issued reports about the company. JPMorgan Chase & Co. raised Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and lifted their price target for the stock from $21.00 to $23.00 in a research report on Monday, May 12th. Bank of America raised their price objective on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the stock a "buy" rating in a research note on Thursday, May 8th. Truist Financial began coverage on shares of Teva Pharmaceutical Industries in a research note on Wednesday, May 28th. They set a "buy" rating and a $25.00 target price for the company. The Goldman Sachs Group initiated coverage on shares of Teva Pharmaceutical Industries in a report on Friday, June 6th. They issued a "buy" rating and a $24.00 price target for the company. Finally, UBS Group dropped their price objective on shares of Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating on the stock in a report on Thursday. Nine research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $24.00.

Teva Pharmaceutical Industries Price Performance

NYSE TEVA opened at $16.62 on Friday. The stock has a 50-day simple moving average of $16.60 and a 200 day simple moving average of $17.41. Teva Pharmaceutical Industries has a twelve month low of $12.47 and a twelve month high of $22.80. The stock has a market capitalization of $19.06 billion, a PE ratio of -14.45, a P/E/G ratio of 0.87 and a beta of 0.60. The company has a debt-to-equity ratio of 2.59, a quick ratio of 0.74 and a current ratio of 1.03.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported $0.52 earnings per share for the quarter, topping analysts' consensus estimates of $0.47 by $0.05. Teva Pharmaceutical Industries had a negative net margin of 7.74% and a positive return on equity of 45.44%. The firm had revenue of $3.89 billion during the quarter, compared to analyst estimates of $3.99 billion. During the same quarter in the previous year, the business earned $0.48 EPS. The business's revenue was up 1.9% on a year-over-year basis.

Insiders Place Their Bets

In other news, EVP Matthew Shields sold 6,206 shares of the company's stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $17.02, for a total value of $105,626.12. Following the sale, the executive vice president now directly owns 9,989 shares in the company, valued at approximately $170,012.78. This represents a 38.32% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 0.49% of the company's stock.

Institutional Trading of Teva Pharmaceutical Industries

Institutional investors have recently bought and sold shares of the stock. Oarsman Capital Inc. acquired a new position in Teva Pharmaceutical Industries during the fourth quarter worth $29,000. Golden State Wealth Management LLC bought a new stake in shares of Teva Pharmaceutical Industries in the 1st quarter worth about $39,000. New Age Alpha Advisors LLC acquired a new stake in shares of Teva Pharmaceutical Industries during the 1st quarter worth about $43,000. Marshall & Sterling Wealth Advisors Inc. acquired a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter worth about $44,000. Finally, Compagnie Lombard Odier SCmA bought a new position in Teva Pharmaceutical Industries during the 1st quarter valued at about $54,000. Institutional investors and hedge funds own 54.05% of the company's stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.